PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Physostigmine has been used as an ocular hypotensive agent to reduce intraocular pressure and manage glaucoma [PMID:31424845, PMID:30208150].
Physostigmine was commonly used to manage and treat antimuscarinic toxicity [PMID:31424845].
Physostigmine served as a chemical template for the development of synthetic drugs such as rivastigmine used in treating Alzheimer's disease [PMID:22329652, PMID:21639405, PMID:29248451].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 31424845 (2026) — Glaucoma-Intraocular Pressure Reduction. · Handbook of experimental pharmacology
- 2.PMID: 15556497 (2004) — Biologically active components of Physostigma venenosum. · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
- 3.PMID: 30208150 (2018) — Nature as a source of drugs for ophthalmology. · Arquivos brasileiros de oftalmologia
- 4.PMID: 21131876 (2011) — A history of glaucoma pharmacology. · Optometry and vision science : official publication of the American Academy of Optometry
- 5.PMID: 22329652 (2012) — Ethnobotanical treatment strategies against Alzheimer's disease.